untitled

Introducing REBETRON^TM Combination Therapy
REBETOL® (Ribavirin, USP) Capsules
INTRON® A (Interferon alfa-2b, recombinant) Injection

Achieves 46%* sustained virologic response in relapsers

Sustained loss of detectable HCV RNA...

46% of patients (79/173) remained HCV-RNA negative at 24 weeks posttreatment^†

*Combined results from two multicenter, randomized, double-blind studies of 345 chronic hepatitis C patients who relapsed after initial response to interferon therapy. Dosing regimen/duration: INTRON^® A 3 MIU TIW plus either placebo or REBETOL^® 1200 mg daily (1000 mg daily for patients weighing <75 kg) for 24 weeks of off-therapy follow-up. Results: Study 1 (n=153): Sustained virologic response in 33/77 REBETRON Combination Therapy patients vs. 3/76 INTRON A/placebo patients. Study 2 (n=192): Sustained virologic response in 46/96 REBETRON Combination Therapy patients vs. 5/96 INTRON A/placebo patients.

...Improves liver histology

63%^‡ of biopsied patients (87/139) showed histologic improvement vs. 41% of patients (57/138) receiving INTRON® A plus placebo

...And 94% of patients (172/173) completed the entire course of treatment

† Defined as HCV RNA below limits of detection using a research-based RT-PCR assay at 24 weeks posttreatment.
‡ Combined results: Study1: 38/61 (REBETRON Combination Therapy) vs. 27/64 (INTRON® A plus placebo). Study 2: 49/78 (REBETRON Combination Therapy) vs. 30/74 (INTRON® A plus placebo). Measured as a decrease of two or more points from pretreatment in Knodell Histology Activity Index (HAI).